Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

February 24, 2020February 24, 2020

Stelara Leads to High Clinical Response, Remission in Severely Active Crohn’s, Phase 3 Study Shows

News

Almost 80% of patients with severely active Crohn’s disease (CD) responded to treatment with Stelara (ustekinumab) and two-thirds achieved clinical remission, according to 16-week results from a Phase 3 clinical trial. ... Read more

February 12, 2020February 12, 2020

One in Six IBD Patients Meet Criteria for Substance Use Disorder (SUD), Study Suggests

News

One in six patients with inflammatory bowel disease (IBD) experience a substance use disorder (SUD), or drug or alcohol addiction, a study suggests. In particular, people with IBD with a ... Read more

January 13, 2020January 13, 2020

Anti-Interleukin-1α Antibody May Be Potential IBD Therapy, Study in Mice Suggests

News

By blocking a key player in gut inflammation, a molecule called interleukin-1α (IL-1α) was highly effective at reducing disease severity in a mouse model of inflammatory bowel disease (IBD), a ... Read more

December 18, 2019December 18, 2019

FDA Approves Extended-Release Xeljanz for Adults with Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer‘s extended-release tablets of Xeljanz XR (tofacitinib) to treat adults with moderately to severely active ulcerative colitis. This approval of 11 mg ... Read more

November 22, 2019November 22, 2019

FDA Approves Pfizer’s Abrilada, Biosimilar to Humira, for IBD and Other Inflammatory Disorders

News

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seven inflammatory disorders, including adult Crohn’s disease and ... Read more

November 18, 2019November 18, 2019

Mice Exposed to High-Sugar Diet More Susceptible to IBD, Especially Colitis, Study Shows

News

A high-sugar diet may increase susceptibility to inflammatory bowel diseases (IBD), and specifically colitis, a study in mice suggests. Titled “A high-sugar diet rapidly enhances susceptibility to colitis via depletion ... Read more

November 13, 2019November 13, 2019

Feeding Infants the Probiotic Bifidobacterium infantis Led to Significantly Lower Intestinal Inflammation, Study Shows

News

Intestinal inflammation was significantly lower in infants that were fed the bacteria B. infantis along with breast milk than in infants that were solely breastfed, a study shows. These findings ... Read more

November 11, 2019November 11, 2019

1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces

News

The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn’s disease, the company announced. Still recruiting at ... Read more

September 9, 2019

Blocking FN14 Protein May Prevent Intestinal Inflammation, Help Treat Crohn’s Disease, Study Says

News

Inhibiting the inflammatory molecule Fn14 with new compounds or antibodies may reduce inflammation and tissue scarring in people with Crohn’s disease, a study suggests. The study, “TWEAK/Fn14 Is Overexpressed in ... Read more

August 30, 2019August 30, 2019

InDex’s Cobitolimod Meets Primary Endpoint of Clinical Remission in Ulcerative Colitis Study, Results Show

News

A larger proportion of people treated with the highest dose of InDex Pharmaceuticals‘ investigational therapy cobitolimod achieved clinical remission compared with those treated with placebo, according to the results of ... Read more